BridgeMD
New treatment option for Acute Neurological Injury
Official title Transcutaneous Auricular Vagus Enhanced Recovery in the NeuroICU
ClinicalTrials.gov ID: NCT07219108
What this study is testing
- What it's testing
- This study will demonstrate the impact of taVNS on reducing adverse events in NeuroICU patients, determine if taVNS reduces length of stay, and quantify the economic benefits of taVNS implementation in a broader neurocritical care population.
- Time commitment: about 1 year
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18
- Admission to the NeuroICU within 36 hours of onset of an acute medical condition.
- Patient or authorized legal representative should be able to provide consent within 36 hours of ICU arrival
- Presence of at least one predictor of critical illness and/or severe brain / spinal cord injury:
- Glasgow Coma Scale GCS \>3 \& \<= 12 at admission
You likely can't join if
- Systemic immunosuppression
- Receiving ongoing cancer therapy
- Implanted electrical device (e.g., pacemaker, stimulator)
- Bradycardia on admission (Sustained bradycardia on arrival with a heart rate \ 5 minutes)
- Risk of imminent death or limitation of care (e.g., Glasgow Coma Scale of 3, pupillary dilatation)
- Expected ICU stay of less than 72 hours, as determined by attending physician or ICU fellow
See the full eligibility criteria
- Age ≥18
- Admission to the NeuroICU within 36 hours of onset of an acute medical condition.
- Patient or authorized legal representative should be able to provide consent within 36 hours of ICU arrival
- Presence of at least one predictor of critical illness and/or severe brain / spinal cord injury:
- Glasgow Coma Scale GCS \>3 \& \<= 12 at admission
- NIH stroke scale of 6 or greater
- Requirement for ongoing mechanical ventilation
- Requirement for ongoing vasopressor support
- Diagnosis of subarachnoid hemorrhage
- Diagnosis of intracerebral hemorrhage with hematoma volume \> 5 ml
- Diagnosis of moderate-severe traumatic brain injury (GCS \>3 \& \<= 12)
- Refractory Status epilepticus requiring continuous sedative infusions
- Systemic immunosuppression
- Receiving ongoing cancer therapy
- Implanted electrical device (e.g., pacemaker, stimulator)
- Bradycardia on admission (Sustained bradycardia on arrival with a heart rate \ 5 minutes)
- Risk of imminent death or limitation of care (e.g., Glasgow Coma Scale of 3, pupillary dilatation)
- Expected ICU stay of less than 72 hours, as determined by attending physician or ICU fellow
- Pregnancy
- COVID-19
The study team makes the final eligibility decision.
Where it's taking place
- St Louis, Missouri, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 1 year per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include St Louis, Missouri, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.